Purification of L-selection(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes

Journal of Immunology

Volumn 160, Issue 7, 1998, Pages 3444-3452

  Kagamu, Hiroshi ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; L SELECTIN; CYTOKINE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL ISOLATION; CYTOPATHOGENIC EFFECT; DELAYED HYPERSENSITIVITY; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; CELL CULTURE; CELL SEPARATION; CYTOTOXICITY; FIBROSARCOMA; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPH NODE; LYMPHOCYTE ACTIVATION; METHODOLOGY; SARCOMA; SECRETION; TRANSPLANTATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CELLS, CULTURED; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FIBROSARCOMA; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; L-SELECTIN; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; SARCOMA, EXPERIMENTAL; TUMOR CELLS, CULTURED;

EID: 0032034214     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Shu S., S. E. Strome, J. C. Krauss, G. E. Plautz, and A. E. Chang. 1994. Tumor-draining lymph nodes as a source for generating therapeutic immune T cells. In Immunotherapy of Cancer with Sensitized T Lymphocytes, A. E. Chang and S. Shu, eds. R. G. Landes Co., Austin, TX, p. 1.
2. Rosenberg, S. A., and W. Terry. 1977. Passive immunotherapy of cancer in animals and man. Adv. Cancer Res. 25:323.
3. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
4. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 223:1318.
5. Barth, R. J. Jr., S. N. Bock, J. J. Mulé, and S. A. Rosenberg. 1990. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J. Immunol. 144:1531.
6. Rosenberg, S. A., B. S. Packardk, P. M. Aebersold, D. Soloman, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. P. Wei, and D. E. White. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N. Engl. J. Med. 319:1676.
7. Yoshizawa, H., A. E. Chang, and S. Shu. 1991. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 147:729.
8. Sussman, J. J., W. L. Wahl, A. E. Chang, and S. Shu. 1995. Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors. J. Immunother. 18:35.
9. Peng, L. S., S. Shu, and J. C. Krauss. 1997. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell. Immunol. 178:24.
10. Kagamu, H., J. E. Touhalisky, G. E. Plautz, J. C. Krauss, and S. Shu. 1996. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res. 56:4338.
11. Van Pel, A., P. van der Bruggen, P. G. Coulie, V. G. Brichard, B. Lethé, B. van den Eynde, C. Uyttenhove, J. C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145:229.
12. Rosenberg, S. A. 1997. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18:175.
13. - T cells: tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161: 1122.
14. Shu, S., and S. A. Rosenberg. 1985. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 45:1657.
15. Wahl, W. L., J. J. Sussman, S. Shu, and A. E. Chang. 1994. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. J. Immunother. 15:242.
16. + tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
17. Jung, T. M., W. M. Gallatin, I. L. Weisman, and M. O. Dailey. 1988. Down-regulation of homing receptors after T cell activation. J. Immunol. 141:4110.
18. Hamann, A., D. Jablonski-Westrich, K. U. Scholz, A. Duijvestijn, E. C. Butcher, and H. G. Thiele. 1988. Regulation of lymphocyte homing. J. Immunol. 140:737.
19. Steen, P. D., J. R. McGregor, C. M. Lehman, and W. E. Samlowski. 1989. Changes in homing receptor expression on murine lymphokine-activated killer cells during IL-2 exposure. J. Immunol. 143:4324.
20. - cells that secretes interleukin 2 (IL-2) IL-3, IL-4, and interferon-γ. J. Exp. Med. 174:547.
21. α during the differentiation of cytotoxic T lymphocytes induced by allografts. J. Immunol. 148:2348.
22. Bevilacqua, M. P., and R. M. Nelson. 1993. Selectins. J. Clin. Invest. 91:379.
23. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
24. Shu, S., T. Chou, and S. A. Rosenberg. 1987. Generation from tumor-bearing mice of lymphocytes with in vitro therapeutic efficacy. J. Immunol. 139:295.
25. Chou, T., A. E. Chang, and S. Shu. 1988. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J. Immunol. 140:2453.
26. Yoshizawa, H., A. E. Chang, and S. Shu. 1992. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res. 52:1129.
27. Mosmann, T. R., and S. Subash. 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17:138.
28. Kelso, A. 1995. Th1 and Th2 subsets: paradigms lost? Immunol. Today 16:374.